Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

How fast you lose weight on tirzepatide may predict how well you keep it off. A post hoc analysis of the SURMOUNT-MAINTAIN trial found that greater early weight loss — especially in the first 60 weeks — significantly raised the odds of maintaining at least 75% of that loss long-term. Demographic and cardiometabolic factors, however, had no bearing on maintenance outcomes.
New data presented at ObesityWeek suggests that early weight loss on tirzepatide (Zepbound, Eli Lilly) is a strong predictor of long-term weight maintenance. In a post hoc analysis of the SURMOUNT-MAINTAIN phase 3 trial, adults who shed more weight during the first 60 weeks of therapy were significantly more likely to maintain at least 75% of that loss — regardless of their demographic or cardiometabolic profile.
Notably, even patients who titrated down to the 5 mg dose showed a maintenance advantage if they lost more weight early on — including within just the first 8 weeks. Researchers say these findings can help clinicians have more informed, patient-centered conversations about weight maintenance strategies.
By the Numbers:
Why it matters: For clinicians managing patients on GLP-1/GIP therapies, early weight loss trajectory could become a practical, real-world tool for guiding dosing decisions and setting realistic long-term expectations — no lab work required.